VEGFA and neoplasm: Bevacizumab. Bevacizumab, a humanized anti-VEGF-A monoclonal antibody which directly targets VEGF-A, reduced the proportion of Tregs in tumor-bearing mice and in patients with metastatic colorectal cancer (mCRC) (25, 66).